Ann: Race In-person Investor Briefing Invitation Perth, page-34

@Davisite

Totally different scenarios.

The GenesisCare liquidation resulted in overwhelming volume being dumped on market. JC's exit (to date) has been a nominal % of traded free float. RAC SP has risen from a low of $.064 to a high of $2.09 during this time. CU6 was crushed from ~$1.20 to ~$0.70 during the GenesisCare liquidation.

RAC took a beating for a number of reasons, one of those being RC220 was targeted for first dosing 12 months ago. CU6 has delivered numerous successes in the clinic. Not the same... and this narrative doesn't help us.